Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus

NCT ID: NCT01870024

Last Updated: 2018-10-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 434 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-06-26
• Study Completion Date: 2018-02-23

Brief Summary

The main purpose of this study is to know on one hand if lorazepam is more (effective) than clonazepam and on the other hand if lorazepam is also effective as the association clonazepam + fosphenytoin in out-of-hospital treatment of the generalized convulsive status epilepticus in adult patients.

Detailed Description

Background: Early and rapid termination of status epilepticus with intravenous administration of benzodiazepines only or its association with other antiepileptic drug improves outcomes. Our out-of-hospital study aims to demonstrate on one hand the superiority of lorazepam compared with clonazepam and on the other hand the efficacy at least equivalent of lorazepam in comparison with the association clonazepam + fosphenytoin. If these hypotheses are demonstrated, the out-of-hospital treatment of the status epilepticus by lorazepam in monotherapy would then be strongly recommended, considering its efficacy and the simplicity of administration in the context of the pre-hospital emergency.Objective: To compare the efficacy of Lorazepam with that of Clonazepam and its association with Fosphenytoin for the treatment of out-of-hospital status epilepticus.

Participating centers: 41 prehospital emergency services employing mobile intensive care units and located in urban areas in France participated in this study. In France, the management of out-of-hospital medical emergencies is under the responsibility of the Service d'Aide Medicale Urgente (SAMU). Mobile intensive care units are staffed by an attending emergency physician or anesthesiologist, a nurse, and an ambulance driver. The study is coordinated by the prehospital emergency service of Lariboisiere Hospital, University Paris 7 (Paris, France)

Number of patients: 522 patients; 174 patients by group.

Duration of the study: The total duration planned is of 48 months Intermediate analysis: An intermediate analysis is planned while 261 patients will be included (50 % of the inclusions).Duration of participation of every patient: 24 hours Data collection: prehospital data recording during the 60 min period of the study, and intrahospital data recording by the medical report of hospitalization.

Methodology: Multicenter, randomized, double-blind trial with 3 arms.

Main criteria of evaluation: the cessation of the status epilepticus and the absence of recurrence from T20 minutes until T60 minutes after the beginning of the treatment.

The cessation of the status epilepticus is defined by the stop of any motor activity and any seizures or convulsive movements. The absence of recurrence is defined by the not occurrence of a new seizures after a period of cessation.

Conditions

Status Epilepticus; Epilepsy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

1: Lorazepam + Placebo

\[ L + P \] = lorazepam 0,1mg/kg by intravenous injection over a period of 2 to 3 minutes) + placebo 20 mg/kg by intravenous infusion over a period of 15 minutes

Group Type: ACTIVE_COMPARATOR

Placebo

Intervention Type: DRUG

placebo 20 mg/kg by intravenous infusion over a period of 15 minutes

Lorazepam

Intervention Type: DRUG

lorazepam 0,1mg/kg by intravenous injection over a period of 2 to 3 minutes)

2: Clonazepam + Placebo

\[ C + P \] = clonazepam 0,015 mg/kg by intravenous injection over a period of 2 to 3 minutes + placebo 20 mg/kg by intravenous infusion over a period of 2 15 minutes

Group Type: ACTIVE_COMPARATOR

Clonazepam

Intervention Type: DRUG

clonazepam 0,015 mg/kg

Placebo

Intervention Type: DRUG

placebo 20 mg/kg by intravenous infusion over a period of 15 minutes

3: Clonazepam + Fosphenytoin

\[ C + F \] = clonazepam 0,015 mg/kg by intravenous injection over a period of 2 to 3 minutes + fosphenytoin 20 mg/kg Equivalent Phenytoin (EP) by intravenous infusion over a period of 15 minutes

Group Type: ACTIVE_COMPARATOR

Clonazepam

Intervention Type: DRUG

clonazepam 0,015 mg/kg

Fosphenytoin

Intervention Type: DRUG

fosphenytoin 20 mg/kg Equivalent Phenytoin (EP) by intravenous infusion over a period of 15 minutes

Interventions

Clonazepam

clonazepam 0,015 mg/kg

Intervention Type: DRUG

Fosphenytoin

fosphenytoin 20 mg/kg Equivalent Phenytoin (EP) by intravenous infusion over a period of 15 minutes

Intervention Type: DRUG

Placebo

placebo 20 mg/kg by intravenous infusion over a period of 15 minutes

Intervention Type: DRUG

Lorazepam

lorazepam 0,1mg/kg by intravenous injection over a period of 2 to 3 minutes)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients aged 18 years or older
• Out-of-hospital management
• presenting one of the criteria below noticed by the physician of the mobile intensive care unit:

1. convulsive seizures at the time of treatment and were reported by reliable witnesses to have been continuously convulsing for longer than 5 minutes, without regaining consciousness, or

2. if they were having more than 2 repeated convulsive seizures at the time of treatment without regaining consciousness

Exclusion Criteria

• Patient having been already included in the study during a previous episode of status epilepticus
• Patient having already received before the arrival of the mobile intensive care unit one of theses studied drugs (lorazepam, clonazepam or fosphenytoin or phenytoin)
• Latent status epilepticus in deep coma
• Cerebral anoxia (post cardio respiratory arrest)
• Severe head trauma
• Patient presenting convulsive seizures of psychogenic origin
• Lennox Gastaut's syndrome
• Decision of urgent intubation
• Patients of more than 110 kg ( estimated weight
• Heart rate < 60 bpm or > 150 bpm
• Systolic Blood Pressure < 90 mmHg
• Atrioventricular block of 2nd or 3rd degree
• Ventricular tachycardia or ventricular fibrillation
• Sensibility known about benzodiazepines, fosphenytoin, phenytoin, other hydantoins, or barbiturate
• Contraindication known about benzodiazepines (severe respiratory failure, severe acute hepatic failure, myasthenia, syndrome of sleep apnea, glaucoma with closed angle
• Contraindication known about fosphenytoin (intermittent acute porphyry)
• Contraindication known about barbiturate (porphyry, severe respiratory failure, current treatment by saquinavir, ifosfamide and voriconazole, in association with millepertuis)
• Person unaffiliated in a National Social Security Insurance
• Pregnant or breast-feeding Woman
• Impossibility to put an intravenous or intra-osseous catheter for the treatment injection
• Absence of nurse in the mobile intensive care unit.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Papa GUEYE, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Assistance Publique - Hôpitaux de Paris

François CONCINA, MD

Role: PRINCIPAL_INVESTIGATOR

CHU Toulouse - Hôpital Purpan

Locations

Département d'Anesthésie - Réanimation - SMUR - Hôpital Lariboisière

Paris, , France

Countries

France

Other Identifiers

2012-003795-39

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

P110123

Identifier Type: -

Identifier Source: org_study_id